Diurnal extends relationship with Consilient

23 February 2021
diurnal-large

UK-based specialty pharma firm Diurnal Group (AIM: DNL) said today that it has extended its distribution arrangements with Ireland-headquartered Consilient Health to include the distribution and marketing of Chronocort (modified-release hydrocortisone) in the Nordic region (consisting of Sweden, Norway, Denmark, Finland and Iceland).

Under the terms of this agreement, Consilient Health, a pharmaceutical company with a track record in commercializing products for endocrinology, women's health and urology, will receive the exclusive rights to market and sell Chronocort when approved, in the Nordics. The region represents a significant market opportunity for Diurnal, with around 2,300 adult patients suffering from congenital adrenal hyperplasia (CAH), providing an estimated total market opportunity for Chronocort of round 11.5 million euros ($14 million) per annum.

EMA marketing approval decision expected this quarter

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical